An observational study in Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant and ATLG, sponsored by Ciceri Fabio. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Ciceri Fabio · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.
Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 59th largest by planned enrollment of the 59 observational ones that give a count, is one of 11 that started in 2026, is one of 59 observational ones, reaches primary completion later than 76 of the 89 other live ones, and was the 284th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:
University of Catania · Sites in Italy
Ages 20–40 · Healthy volunteers
Azienda Usl di Bologna · Sites in Italy
Ages 18–65
Sanofi · Sites in Italy, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Italy, Belgium, Spain
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 40 · Phase 3 66 · Phase 4 19
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 115 across the 230 interventional studies, 214 across the 59 observational. Of the 164 that completed or were terminated, 77 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 289 have an industry lead sponsor. The 10 most frequent:
Ciceri Fabio is the lead sponsor of 8 studies on the registry; 6 are open to participants now.
Ciceri Fabio has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT05748015Istituti Clinici Scientifici Maugeri SpADefinition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis | 2026-11-30 |
| NCT07502066IRCCS San Camillo, Venezia, ItalyClinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases | 2026-12 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 289 studies in Multiple Sclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, observational, biological, multicenter study to investigate IR profile, ATLG dynamics, main HSCT and disease outcomes in MS. This study will provide a preliminary descriptive evaluation of key study parameters, including ATLG pharmacokinetics and immune reconstitution trends, as well as an initial assessment of variability (e.g., dispersion of immunological biomarkers), to support the interpretation of results and the design of future studies. Since this is an observational study, no clinical decision will be made, and the interim analysis will not have an impact of the study conduction, and it will not be a stopping rule.
The study will involve 20 MS patients, treated with autologous HSCT as standard-of-care according to guidelines and consensus recommendations. Autologous HSCT is considered a standard-of-care intervention in the following selected MS patients: RRMS who have failed to respond to one or more high-efficacy DMTs or progressive MS with superimposed inflammatory activity, or aggressive forms of MS where rapid neurological decline occurs early in the disease course.
Patients will receive standard conditioning regimen (BEAM or cyclophosphamide) and ATLG (total dose 30 mg/kg over 3 days: 10 mg/kg on days -3, -2 and -1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study will involve 20 Multiple Sclerosis (MS) patients, treated with autologous HSCT as standard-of-care according to guidelines and consensus recommendations. Autologous Hematopoietic stem cell transplantation (HSCT) is considered a standard-of-care intervention in the following selected MS patients: RRMS who have failed to respond to one or more high-efficacy Disease modifying therapies (DMTs) or progressive MS with superimposed inflammatory activity, or aggressive forms of MS where rapid neurological decline occurs early in the disease course.
Drug: ATLG administration
Patients will receive standard conditioning regimen (BEAM or cyclophosphamide) and ATLG (total dose 30 mg/kg over 3 days: 10 mg/kg on days -3, -2 and -1).
Investigate immune status in correlation with ATLG
Longitudinal IR monitoring (T/B/NK lymphocyte subpopulations including naïve- memory- stem/memory- regulatory subsets, cytokine profile, NFL/Macrophages) on PB
Time frame: before mobilization, before conditioning, +1/3/6/12 months after HSCT.
Investigate immune status in correlation with ATLG
Assessment of ATLG levels \& kinetics
Time frame: before and 30' after the end of ATLG dose, day0, day1, weekly for 4 weeks.
Assess clinically relevant viral infections in correlation with viral specific IR
Assessment of pathogen-specific responses (CMV specific T cells by ELISpot) and occurrence of clinically relevant viral infections (CMV, EBV; ECIL 10 guidelines).
Time frame: before mobilization, +1 month after HSCT within the first year after HSCT.
To assess HSCT and neurological outcomes
Transplant-related mortality (TRM)
Time frame: at 100 days and 1-year
Assessment of Progression Free Survival (PFS)
Assessment of general HSCT outcomes (PFS)
Time frame: at 1-year
Assessment of Overall survival (OS)
Assessment of general HSCT outcomes - OS
Time frame: At 1 year
neurological status- Expanded Disability Status Scale (EDSS)
Expanded Disability Status Scale (EDSS)
Time frame: at 100 days, 6 months and 1-year
neurological status - neurological progression
neurological status - neurological progression
Time frame: at 1 year
neurological status -No Evidence of Disease Activity
No Evidence of Disease Activity (NEDA)
Time frame: At 1 year
Plan to share: Undecided
Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 24 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ciceri Fabio